Two virulence markers, cagA and babA2, were characterized by PCR in 101 Helicobacter pylori isolates from a population in Taiwan. cagA was detected in 99% of the isolates, while babA2 was present in all of the isolates. Base deletions and substitutions at the forward babA2 primer annealing sites were found. Given their high prevalence, cagA and babA2 cannot be useful markers for predicting the high-risk patients of H. pylori infection in Taiwan.

No abstract

Dryout in a heat pipe evaporator is caused by insufficient condensate supply through the wick structure. Dryout is generally considered a failure of the heat pipe operation. However, traditional dryout theory may not fully explain the heat and mass transport limitations in the biporous (biwick) wick structure due to new mass transfer mechanisms, such as liquid splash at high heat flux, and vapor bubble/jet occupation of liquid transport passages. This article investigates the dryout phenomenon in carbon nanotube (CNT) based biwick structure. The incipience and expansion of the dryout zone on the CNT biwick structure are visualized. Variation of the evaporator temperatures at various heat fluxes is measured to characterize the temperature responses on the biwick dryout. Results based on both visualization and measurement show that dryout of CNT biwick structures is affected by vapor flow induced droplet splash and vapor occupation of liquid transport passages, which reduces the liquid supply to the hottest region and creates a local dry zone. On the curves of heat flux versus the evaporator temperature, dryout can be defined as the appearance of the inflexion point during the heating period, and associated with the existence of a large temperature hysteresis in a heating and cooling cycle. Experimental measurement also shows that over 12% of the liquid by volume is lost without being phase changed, due to high-speed vapor flow induced liquid splash. Liquid splash and interactions between vapor and liquid flows also increase the pressure drop weight in the evaporator over the system loop and result in more notable heating area effect on biwick structures when compared with traditional monowick structures.

1023 Background: GDC-9545 is a potent, orally available, selective estrogen receptor degrader developed for the treatment of ER-positive (ER+) breast cancer alone or combined with CDK4/6 inhibitors. A first-in-human study evaluated 10-250 mg GDC-9545; tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical results support expansion cohorts at ≥30 mg (Jhaveri et al., 2019). Methods: This study evaluated PK, PD, and efficacy of GDC-9545 alone and combined with palbociclib, ± LHRH agonist. Eligible patients (pts) had ER+ (HER2-) metastatic breast cancer (MBC) with ≤ 2 prior therapies in the advanced or metastatic setting. No prior treatment with CDK4/6 inhibitor was allowed in pts receiving palbociclib. Results: Eight-five pts were enrolled in 2 cohorts: GDC-9545 100 mg given once daily ± LHRH agonist (Cohort A), and GDC-9545 100 mg +125 mg palbociclib on a 21 day on/7 day off schedule ± LHRH agonist (Cohort B). Of the 39 pts in Cohort A, adverse events (AE) occurring in ≥10% of pts were fatigue, cough, back pain, pain in extremity, and arthralgia. Related AEs were generally Grade (G) 1-2; there were 3 related G3 AEs of fatigue, transaminase increased, and diarrhea. Two pts had GDC-9545 reduced, one due to G3 diarrhea and another due to G3 transaminitis. Of the 46 pts in Cohort B, AEs in ≥10% of pts were neutropenia, fatigue, bradycardia, diarrhea, constipation, dizziness, nausea, anemia, asthenia, thrombocytopenia, pruritus, and visual impairment. Twenty-six (57%) pts had G≥3 AEs. G≥3 neutropenia was reported in 23 (50%) pts. One pt had palbociclib reduced due to G3 febrile neutropenia. Eleven (13%) of 85 pts had G1 asymptomatic bradycardia considered related to GDC-9545. No pts in either cohort discontinued study treatment due to AEs. PK analysis and clinical data demonstrate no clinically relevant drug-drug interactions between GDC-9545 and palbociclib. Reduced ER, PR, and Ki67 levels, and an ER activity signature, were observed in paired pre- and on-treatment biopsies (n = 12). Eighteen of 33 pts in Cohort A had either confirmed partial responses or were on study 24 weeks (clinical benefit rate 55%). Clinical benefit was observed in pts with prior fulvestrant treatment and with detectable ESR1 mutations at enrollment. Clinical benefit data for both cohorts are anticipated to be mature in April 2020. Conclusions: GDC-9545 was well-tolerated as a single agent and in combination with palbociclib with encouraging PK, PD, and anti-tumor activity in ER+ MBC to support Phase III development. Clinical trial information: NCT03332797 .

No abstract